Rebond ou krash ? - Avant Bourse TradOx 09 Octobre 2022
- 111
TradOx
Lastest news
- IO Biotech Showcases Scientific Leadership Through Cancer Vaccines Educational Session at the American Association for Cancer Research (AACR) Annual Meeting 2025
- Medtronic Expand URO U.S. clinical trial meets safety and effectiveness primary endpoints for Hugo™ robotic-assisted surgery system
- Johnson & Johnson's TAR-200 monotherapy achieves high disease-free survival of more than 80 percent in BCG-unresponsive, high-risk papillary NMIBC
- Johnson & Johnson's TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in patients with certain types of bladder cancer
- QUBT DEADLINE NOTICE: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Quantum Computing Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important April 28 Deadline in Securities Class Action - QUBT
- Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Lastest videos
